Cirrhosis clinical trials
79 active trials name this condition. Describe your situation to see which ones you may be eligible for.
By location
- Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
- Intestinal Microbiota Transplant in Alcohol-Associated Liver Disease
- High Dose Albumin in Refractory Ascites
- A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)
- Affect of Melatonin on Sleep and Cognition in Cirrhosis
- Copper Supplementation in Cirrhosis
- A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- Danazol for Treatment of Cytopenias in Patients With Cirrhosis
- Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
- Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease
- Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
- Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
- Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics
- Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis
- Bumetanide vs. Furosemide in Cirrhosis
- Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
- Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease
- Initial Resuscitation for Acute Kidney Injury in Cirrhosis
- The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial
- Remote Electrical Stimulation for Pain and Depression Treatment in Cirrhosis
- A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
- Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
- Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
- Late Evening and Early Morning Protein Supplement to Reduce Readmissions for Hepatic Encephalopathy
- EGCG for Hepatocellular Carcinoma Chemoprevention
- Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk
- Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
- Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement
- CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules
- Developing Viability Index for Machine Perfused Livers
- Liver Cancer Disparities in American Indian and Alaska Native Persons
- Adverse Outcomes and Mortality in Liver Transplant
- National Liver Cancer Screening Trial
- Prospective Investigation of Cirrhotic Cardiomyopathy in Humans
- Measuring Patient Reported Needs in Outpatient Liver Disease Management
- Changes in Glucose Tolerance in Patients With Cirrhosis Peri-Liver Transplant
- Multi-analyte Blood Test Clinical Trial
- Validation of CAGIB Score for In-hospital Mortality of Cirrhotic Patients With Acute Gastrointestinal Bleeding
- Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs
- Novel Tracer Methods to Evaluate Muscle Protein Metabolism in Cirrhosis
- Functional Assessment in Liver Transplantation
- Mechanisms of Malnutrition in Cirrhosis With Portosystemic Shunting
- Evaluation of Non-Invasive Tests for Metabolic Liver Disease
- Development and Testing of a Patient-facing Educational Tool About Liver Cancer Prevention
- Prevalence of Gastric Motor Dysfunction and Upper GI Symptoms in Gastric Antral Vascular Ectasias
- Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis
- Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
- InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
- Blood Collection Biorepository for Liver Disease Research
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Cirrhosis” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.